Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.63 |
| ▸ | MMP1 | P03956 | 4/20 | 0.62 |
| ▸ | MMP2 | P08253 | 4/20 | 0.62 |
| ▸ | MMP9 | P14780 | 4/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | CDK4 | P11802 | 1/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.60 |
| ▸ | CCND1 | P24385 | 1/20 | 0.60 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | F3 | P13726 | 2/20 | 0.59 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667568 | 1.00 | CYP2C9 (0.63) | CYP2C9CYP1A2HSD17B3MMP1MMP2 | |
| SCHEMBL10021666 | 0.94 | LCK (0.71) | CYP2C9CYP1A2HSD17B3MMP1MMP2 | |
| SCHEMBL10021655 | 0.94 | CYP2C9 (0.70) | CYP2C9CYP1A2HSD17B3MMP1MMP2 | |
| SCHEMBL10021716 | 0.89 | MMP1 (0.65) | CYP2C9CYP1A2HSD17B3MMP1MMP2 | |
| SCHEMBL10021687 | 0.89 | MMP1 (0.65) | CYP2C9CYP1A2HSD17B3MMP1MMP2 | |
| SCHEMBL10021647 | 0.89 | LCK (0.74) | CYP2C9CYP1A2MMP1MMP2MMP9 | |
| SCHEMBL28492979 | 0.89 | MMP1 (0.55) | CYP2C9CYP1A2HSD17B3MMP1MMP2 | |
| SCHEMBL28156567 | 0.88 | CCNB2 (0.53) | CYP2C9CYP1A2HSD17B3MMP1MMP2 | |
| SCHEMBL609310 | 0.87 | FOS (0.68) | MMP1MMP2MMP9MAOAMAOB | |
| SCHEMBL609311 | 0.87 | FOS (0.68) | MMP1MMP2MMP9MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031534-A1 | PESTICIDAL FLAVOBACTERIUM STRAIN AND BIOACTIVE COMPOSITIONS METABOLITES AND USES | PRO FARM GROUP, INC. | 2015-01-29 | — | — | US | claimed |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20210227833-A1 | PESTICIDAL FLAVOBACTERIUM STRAIN AND BIOACTIVE COMPOSITIONS METABOLITES AND USES | MARRONE BIO INNOVATIONS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210227833-A1 | PESTICIDAL FLAVOBACTERIUM STRAIN AND BIOACTIVE COMPOSITIONS METABOLITES AND USES | MARRONE BIO INNOVATIONS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-11013236-B2 | Pesticidal Flavobacterium strain and bioactive compositions metabolites and uses | MARRONE BIO INNOVATIONS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11013236-B2 | Pesticidal Flavobacterium strain and bioactive compositions metabolites and uses | MARRONE BIO INNOVATIONS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| EP-3113767-B1 | MTOR-INDEPENDENT ACTIVATOR OF TFEB FOR AUTOPHAGY ENHANCEMENT AND USES THEREOF | UNIV HONG KONG BAPTIST UNIV (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
| US-20050069551-A1 | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis | EMORY UNIVERSITY | 2005-03-31 | — | — | US | disclosed |
| WO-2005025623-A2 | EF-24-FACTOR VII CONJUGATES | EMORY UNIVERSITY (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2004-09-09 | — | — | US | disclosed |
| US-6664272-B2 | Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue | EMORY UNIVERSITY | 2003-12-16 | — | — | US | disclosed |
| EP-1242379-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | Emory University (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040188-A9 | CURCUMIN ANALOGUES FOR TREATING CANCER | UNIV EMORY (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2002-02-14 | — | — | US | disclosed |
| WO-2001040188-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | EMORY UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | CYP2C9 3818/4885CYP1A2 2166/4885HSD17B3 2643/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | CYP2C9 3299/4885CYP1A2 2544/4885HSD17B3 1637/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | CYP2C9 3818/4885CYP1A2 2166/4885HSD17B3 2643/4885 |
| US-20210227833-A1 | PESTICIDAL FLAVOBACTERIUM STRAIN AND BIOACTIVE COMPOSITIONS METABOLITES AND USES | BLVRB, PRDX6, ACHE | CYP2C9 832/4885CYP1A2 496/4885HSD17B3 1691/4885 |
| US-20150031534-A1 | PESTICIDAL FLAVOBACTERIUM STRAIN AND BIOACTIVE COMPOSITIONS METABOLITES AND USES | BLVRB, PRDX6, ACHE | CYP2C9 832/4885CYP1A2 496/4885HSD17B3 1691/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CYP2C9 3818/4885CYP1A2 2166/4885HSD17B3 2643/4885 |
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | CYP2C9 4568/4885CYP1A2 4542/4885HSD17B3 4093/4885 |
| US-20050069551-A1 | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis | VEGFA, AGER, HDGF | CYP2C9 4122/4885CYP1A2 3281/4885HSD17B3 4121/4885 |
| US-11013236-B2 | Pesticidal Flavobacterium strain and bioactive compositions metabolites and uses | BLVRB, PRDX6, ACHE | CYP2C9 832/4885CYP1A2 496/4885HSD17B3 1691/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CYP2C9 3818/4885CYP1A2 2166/4885HSD17B3 2643/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | CYP2C9 1867/4885CYP1A2 760/4885HSD17B3 881/4885 |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | CYP2C9 4568/4885CYP1A2 4542/4885HSD17B3 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.